高度近视超声乳化及人工晶状体植入术

目的 评价高度近视白内障超声乳化吸出及后房型人工晶状体植入术的效果。方法 对45例（58眼）高度近视白内障行巩膜隧道切口超声乳化吸出、植入5．5mmPMMA硬性人工晶状体于囊袋内。平均年龄57．3岁（42－72岁）。平均眼轴长28．2mm（26．3－32．8mm）。Ⅱ级核12例，Ⅲ级核44眼，Ⅳ级核2眼。结果 术后1月，裸眼或矫正视力≥0．5者44眼占75．8％，其中眼轴长26－30mm组42眼占95．5％，眼轴＞30mm组2眼占4．5％。矫正视力≤0．1者3眼，均有明显而广泛的高度近视性黄斑病变。结论 高度近视白内障超声乳化吸出及后房人工晶状体植入术后视力恢复较快、较好，但眼轴过长（＞30mm）及眼底黄斑病变严重者，视力恢复较差。     

高度近视白内障超声乳化人工晶状体植入术的效果

目的 评价高度近视合并白内障行超声乳化吸出及折叠人工晶状体植术的临床效果.方法 对36例（48眼）高度近视合并白内障行透明角膜切口超声乳化吸出及折叠人工晶状体植入术.眼轴长度（26.78～34.56）mm,平均（27.43±2.80） mm,其中眼轴≤30 nm者36眼;眼轴＞30mm者12眼.观察术后视力及术中术后并发症.结果 术中悬韧带离断1眼,后囊破裂2眼,经处理均植入折叠人工晶状体于囊袋内.眼轴≤30 mm的36跟中术后视力≥0.3者30眼（83.3％）;眼轴＞30 mm的12眼中术后视力≥0.3者5眼（41.7％）.结论 透明角膜切口超声乳化吸出及折叠人工晶状体植入术,适合于高度近视合并白内障.但眼轴＞ 30 mm者术后视力恢复较差,与眼轴长度及黄斑功能有关.     

高度近视白内障超声乳化摘出及人工晶状体植入术

目的 评价高度近视白内障超声乳化及人工晶状体植入术的临床疗效。方法 对眼轴,２６．５ｍｍ的２８例（３８眼）高度近视并发白内障患者,其中Ⅱ级核１０眼,Ⅲ级核２０眼,Ⅳ级核８眼,施行超声乳化及人工晶体植入术,结果 术后１月视力≥０．５者２７眼（７１．１％）,并发症主要包括后囊破裂２眼（５．３％）,角膜水肿６眼（１５．８％）,眼轴〉３０ｍｍ组,视力效果不及眼轴２６．５￣３０ｍｍ组。高度近视合并视网膜病变     

高度近视透明晶状体乳化吸出人工晶状体植入

目的 观察高度近视透明晶状体及合并白内障超声乳化吸出后房型硬性人工晶状体植入的效果。方法 42例(58眼)。透明晶状体12例(22眼)，合并白内障30例(36眼)。均行晶状体超声乳化吸出，5．5mm自闭式巩膜隧道切口植入PMMA硬性人工晶状体，随访3月～1年，观察术后视力及并发症。结果 透明晶状体组：术后1周及3月～1年，视力≥0．3者分别为100％、95．5％；白内障组视力≥0．3者分别为66．7％，72．2％。并发症：透明晶状体组无特殊并发症；白内障组，1眼后囊破裂，2眼角膜中度水肿，6眼后发障(1眼激光治疗)。结论 高度近视晶状体超声乳化吸出及人工晶状体植入安全有效。     

高度近视伴核性白内障表面麻醉下超声乳化治疗观察

目的 探讨高度近视伴核性白内障表面麻醉下超声乳化吸出及人工晶状体植入术的效果.方法 对78例(78跟)高度近视伴核性白内障在表面麻醉下行超声乳化吸出及人工晶状体植入术,观察麻醉满意度,术中及术后并发症.结果 所有患者均在表麻下无痛苦完成手术,术中术后无严重并发症发生.术后1d视力≥0.5者46例(46眼),占58.97％;术后1周视力≥0.5者58例(58眼),占74.35％.结论 表面麻醉下超声乳化白内障吸出术人工晶状体植入是高度近视伴核性白内障较理想的手术方式.     

高度近视白内障超声乳化手术临床观察

目的 探讨高度近视白内障超声乳化吸出人工晶状体植入术的效果。方法 对18例（19眼）高度近视并发白内障施行巩膜膀隧道切口超声乳化吸出，通过5．5mm切口植入PMMA硬性人工晶状体。结果 术后1周裸眼视力：0．12－0．3者占57．8％矫正视力＞0．4者占42．11％。结论 高度近视并发白内障选择超声乳化吸出具有术后视力恢复快，术后并发症少等优点。     

超高度近视白内障超声乳化联合Bigbag晶状体植入疗效观察

目的探讨超高度近视合并白内障行超声乳化吸出联合Bigbag人工晶状体植入术的临床疗效。方法表麻下对25例（30眼）超高度近视合并自内障行超声乳化吸出联合Bi曲ag人工晶状体植入术。术后观察玻璃体的活动度、最佳矫正视力、屈光度和手术并发症。随访1—8个月。结果术后最佳矫正视力≥0．5者共8眼（26．7％）,0．3—0．4者共16眼（53．3％）,〈0．3者6眼（20％）。术中无晶状体后囊破裂。常见情况为术后1d角膜不同程度水肿,在3—10d内自行消退。术后无视网膜及脉络膜脱离,无黄斑囊样水肿或后发障等并发症。结论超声乳化联合Bigb职人工晶状体植人术治疗超高度近视自内障能有效改善视力,增加玻璃体的稳定性,有效降低并发症的发生。     

高度近视白内障超声乳化摘出术

目的 评价高度近视合并白内障超声乳化摘出术的临床疗效。方法 ３６例（４４眼）眼轴长≥２６ｍｍ的高度近视合并白内障,其中Ⅱ级核１０眼,Ⅲ级核３１眼,Ⅳ级核３眼。采用巩膜隧道式切口及囊袋内超声乳化,并植入人工晶状体。结果 术后１月最佳矫正视力≥０．５者２３眼（５２．３％）;手术主要并发症为后囊破裂４眼（９．０９％）,角膜水肿３眼（６．８２％）。视网膜脱离１眼（２．２７％）。结论 超声乳化联合人工晶状体     

高度近视白内障人工晶状体植入术的临床观察

目的　观察超声晶状体乳化吸出联合折叠式人工晶状体植入术治疗白内障合并高度近视的临床效果。方法　对70例 (12 5眼 )白内障合并高度近视行超声乳化吸出低度数或负度数丙烯酸酯折叠式人工晶状体植入术 ,观察术中术后并发症、术后视力和屈光状态。术后随访时间≥ 3月。结果　术中和术后并发症有后囊破裂 3眼 ,角膜水肿 12眼。术后 3月最佳矫正视力 <0 1者 4眼 ,0 1～ 0 4者 2 5眼 ,0 5～ 0 9者 86眼 ,1 0～ 1 5者 10眼。 4眼 (3 2 % )晶状体后囊浑浊 ,无视网膜脱离者。结论　超声乳化吸出低度数或负度数丙烯酸酯折叠式人工晶状体植入术治疗白内障合并高度近视 ,是安全有效的。     

超声乳化人工晶状体植入术治疗高度近视白内障

目的 探讨高度近视白内障患者行超声乳化人工晶状体植入术的疗效。方法 表面麻醉下对160例193眼高度近视白内障患者行超声乳化人工晶状体植入术。结果 眼铀26—30mm组，术后1月视力≥0．5者100眼，占81．97％；眼铀≥30mm组，术后1月视力≥0．5者33眼，占46．48％．结论 超声乳化人工晶状体植入术治疗高度近视白内障患者能改善患者的视力。     

Bilateral CNV associated with optic nerve drusen treated with photodynamic therapy with verteporfin

PURPOSE: To report a case of bilateral choroidal neovascularization (CNV) associated with optic nerve drusen (OND) treated with photodynamic therapy (PDT) with verteporfin. METHODS: A 10-year-old girl with juxtapapillary CNV in the right eye and juxtapapillary and juxtafoveal CNV in the left eye associated with OND underwent PDT with verteporfin in both eyes. RESULTS: Visual acuity increased from 20/160 to 20/25 in the right eye and from 20/1000 to 20/25 in the left eye after two sessions of PDT and 2 years of follow-up. CNV showed no leakage after two PDT sessions in both eyes and no recurrence was observed. CONCLUSIONS: Subfoveal CNV is an uncommon complication of OND and excellent anatomic and functional results can be obtained with PDT.     

合并成型性渗出的急性前葡萄膜炎与HLA-B27的相关性研究

目的 探讨急性渗出性前葡萄膜炎与HLA-B27的相关性。方法 对53例前房内出现成型性渗出的急性前葡萄膜炎（AAUPE）患者及61例前房内无成型性渗出的急性前葡萄膜炎（AAU）患者进行HLA-B27的检测,并结合临床表现加以分析。结果 成型性渗出的AAUPE患者的HLA-B27阳性率为100％,而无成型性渗出的AAU患者的HLA-B27阳性率仅为50.8％。二者有显著差异性（P<0.01）。两组HLA-B27阳性的病人强直性脊柱炎发生率分别为50.0％和42.9％。结论 结果进一步证实了HLA-B27与成型性渗出密切相关的论点。提示检测AAU患者HLA-B27的阳性率,发现成型性渗出裂隙灯检查似与血清法检测同样准确。     

Levodopa-carbidopa with occlusion in older children with amblyopia

PURPOSE: To study the role of levodopa-carbidopa in supplementing occlusion therapy in older children with strabismic or anisometropic amblyopia. Methods: A clinical study was performed on 40 amblyopic children (19 strabismic and 21 anisometropic), 6 to 18 years old (mean age, 10.9 years). They received an average dose of 1.86 mg/kg/day (1.33-2.36 mg/kg/day) of levodopa and carbidopa (4:1 ratio) or a placebo in 3 divided doses over a 4-week period, combined with full-time occlusion. The occlusion was continued for the study duration of 3 months. Early Treatment Diabetic Retinopathy Study visual acuity charts and Cambridge low-contrast gratings for contrast sensitivity (CS) were used to assess visual functions. Tolerance and compliance with occlusion and capsule consumption were assessed. RESULTS: Visual acuity of the nonamblyopic eye did not deteriorate during the study in either group. CS decreased by 22 units in the levodopa group and increased in the placebo group by 53 units at the first month. The CS in the levodopa group recovered later by the third month of follow-up. Both the levodopa and the placebo groups showed significant improvement in visual function in the amblyopic eye (P <.001). Overall changes in logarithm of minimum angle of resolution values and CS in the amblyopic eyes were similar in both groups (P >.05). Strabismic and anisometropic amblyopes did not behave differently. Drug tolerance, occlusion compliance, and capsule ingestion compliance were similar between the groups, with no significant side effects. CONCLUSIONS: Clinically, levodopa supplementation does not offer any advantage over occlusion alone. Moreover, the risk of occlusion amblyopia could increase with the use of drugs like levodopa that might affect the plasticity of the visual cortex.     

Phacotrabeculectomy with mitomycin C in patients with uveitis

PURPOSE: To evaluate the safety and efficacy of combined phacoemulsification, intraocular lens implantation, and trabeculectomy with mitomycin C for the management of uveitic complications. DESIGN: Retrospective case-control study. METHODS: We conducted a retrospective review of the records of 23 consecutive eyes with chronic noninfectious uveitis (uveitic group) and 43 nonuveitic eyes (control group) that had received primary phacotrabeculectomy. Mitomycin C was used in all the uveitic eyes. Considering the high preoperative intraocular pressure (IOP) of the uveitic group, nonuveitic eyes that had a preoperative IOP of >or=20 mm Hg or that had been given two or more medications were included in the control group. All patients were followed for at least one year. The main outcome measures were postoperative vision, IOP control, complications, and acute uveitis relapse rates. RESULTS: Visual outcome of the uveitic group was similar to the control group. In the uveitic group, the success rate of IOP control (91.3% at one year, 84.8% at two years) was favorable but was significantly lower than in the control group (P = .0423). Complications were comparable between the groups. Primary surgical failure in the uveitic group was associated with the postoperative acute uveitis attack. In the uveitic group, the acute uveitis attack rate showed no change after surgery (P = .283). CONCLUSION: With adequate inflammation suppression, phacotrabeculectomy with mitomycin C is an effective and safe therapeutic option for the management of secondary cataract and glaucoma in uveitic eyes. A lower surgical success rate of the uveitic group might be attributable to the postoperative inflammation recurrence.     

Epikeratoplasty with nonlyophilized tissue in children with aphakia

We studied 75 epikeratoplasty procedures using nonlyophilized tissue performed by eight ophthalmic surgeons in 70 eyes (47 patients) to correct for aphakia in children less than 8 years of age (mean age, 3.4 +/- 2.1 years). Of the 47 patients in the study, 24 were girls and 23 were boys; 23 patients had bilateral surgery. Seven of the epigrafts required removal; two were not replaced, and five underwent successful repeat epikeratoplasty. Overall, the success rate (that is, the percentage of epigrafts that remained optically and functionally clear throughout the course of this study) for the epikeratoplasty procedure was 89% (62 of 70 eyes) for initial surgery and 96% (67 of 70 eyes) for repeat surgery. The average spherical equivalent was +14.4 +/- 3.7 diopters preoperatively and +0.3 +/- 2.9 diopters one year after the operation. One year after the final surgical procedure, 42 of 56 eyes (75%) were within 3 diopters of emmetropia. In the 29 verbal patients, best-corrected visual acuity was 20/100 or better in 25 (86.2%) one year after the operation.     

滤过试验结合可拆缝线在小梁切除术中的应用

目的　探讨小梁切除术术中做滤过试验结合可拆缝线的应用对预测和控制术后滤过量及预防浅前房的疗效。方法　对 92例 ( 113眼 )原发性青光眼 ,在小梁切除术术中根据滤过试验结果来决定固定缝线和可拆缝线缝合的位置和数量。术后 1～ 7天 ,抽出可拆缝线。回顾性总结术中缝合种类、数量及术后前房深度、眼压、滤过泡、视野。结果　术中 40眼 ( 3 5 40 % )采用一针固定缝线和一至二针可拆缝线 ,5 1眼 ( 45 14 % )采用二针固定缝线和一至二针可拆缝线。术后无一例持续性浅前房。术后第 7天眼压平均 13 5± 3 3 0mmHg。追踪观察 6～ 2 4个月 ,形成功能性滤过泡 89眼( 78 76% ) ,眼压控制 <2 1mmHg 91眼 ( 80 5 3 % ) ,视野不变 98眼 ( 86 73 % )。结论　小梁切除术术中根据滤过试验的结果 ,通过对固定缝线和可拆缝线缝合的位置和数量的选择能有效预测和控制术后滤过量并预防术后浅前房     

超声乳化联合前房角分离治疗伴白内障的青光眼

目的：：观察晶状体超声乳化联合前房角分离术对伴有白内障的慢性闭角型青光眼患者的治疗效果。方法：无并发症伴有白内障的慢性闭角型青光眼50例50眼,施行晶状体超声乳化吸出人工晶状体植入联合前房角分离术。术后随访3mo,记录并比较术前及术后最佳矫正视力、眼压、前房深度及前房角。各指标均采用均数±标准差(x±s)表示,术前及术后3mo的最佳矫正视力、眼压、前房深度及前房角的情况进行比较。结果：术后3 mo的最佳矫正视力较术前明显提高,差异有统计学意义( t=8.76, P=0.001);术后3 mo 的眼压为15.63±3.11mmHg,较术前(45.12±5.30mmHg)明显下降,差异有统计学意义(t=6.27,P=0.000);术后3mo的前房深度为3.57±0.02mm,较术前(1.43±0.25mm)明显加深,差异有统计学意义(t=8.16,P=0.001);术前、术后前房角情况的比较,差异有统计学意义(Z=-4.432,P=0.000;Z=-2.432,P=0.016;Z=-4.379,P=0.000;Z=-4.538, P=0.000)。结论：晶状体超声乳化吸出人工晶状体植入联合前房角分离术治疗伴有白内障的慢性闭角型青光眼,能够有效控制眼压,提高视力,是一种安全、有效的手术方法。